1190749-75-7

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 112-60-7 Tetraethylene glycol 
• 37860-51-8 tetraethylene glycol di(p-toluenesulfonate) 

Downstream Products

• 1268257-49-3 3-benzo[1,3]dioxol-5-yl-4-{3-(2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)ethoxy)-4,5-dimethoxybenzyl}-5-hydroxy-5-(4-methoxyphenyl)-5H-furan-2-one 
• 1268257-61-9 3-(2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)ethoxy)-4,5-dimethoxybenzaldehyde 

Relevant academic research and scientific papers

Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor

Cannabinoid receptors type 2 (CB2) represent a target with increasing importance for neuroimaging due to its upregulation under various pathological conditions. Encouraged by preliminary results obtained with [11C](Z)-N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-cyclopropanecarboxamide ([11C]A-836339, [11C]1) in a mouse model of acute neuroinflammation (induced by lipopolysaccharide, LPS), we designed a library of fluorinated analogues aiming for an [18F]-labeled radiotracer with improved CB2 binding affinity and selectivity. Compound (Z)-N-(3-(4-fluorobutyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-cyclopropanecarboxamide (29) was selected as the ligand with the highest CB2 affinity (Ki = 0.39 nM) and selectivity over those of CB1 (factor of 1000). [18F]29 was prepared starting from the bromo precursor (53). Specific binding was shown in vitro, whereas fast metabolism was observed in vivo in CD-1 mice. Animal PET revealed a brain uptake comparable to that of [11C]1. In the LPS-treated mice, a 20-30% higher uptake in brain was found in comparison to that in nontreated mice (n = 3, P 0.05).

NOVEL COMPOSITIONS FOR LABELING BIOMOLECULES AND METHODS USING SAME

The present invention includes novel compounds useful for labeling biomolecules. The present invention further includes a novel method of labeling a biomolecule using a compound of the invention. The present invention further includes a novel method of im

Glucopyranosyl derivative and application thereof in medicines

The invention relates to a glucopyranosyl derivative used as a sodium-dependent glucose transporter (SGLT) inhibitor, a medicinal composition containing the derivative, and an application of the derivative and the medicinal composition in medicines, and especially relates to the glucopyranosyl derivative represented by formula (I) or a pharmaceutically acceptable salt or all stereoisomers thereof, or the medicinal composition containing the derivative, and a use of the derivative and the medicinal composition in the preparation of medicines for treating diabetes and diabetes related diseases.